Scholarlink

<p>The genus <i>Artemisia</i> (family Asteraceae) is widely recognized for its medicinal properties, among which artemisinin is the most notable, historically serving as a key antimalarial agent. Accumulating evidence now highlights the significant anticancer potential of <i>Artemisia</i> species, with bioactive compounds such as artemisinin and its derivatives exhibiting promising activity across multiple cancer types. This review provides a comprehensive overview of the molecular mechanisms underlying the anticancer effects of <i>Artemisia</i>-derived compounds, including apoptosis induction, cell cycle arrest, and oxidative stress modulation. In addition, it examines their therapeutic efficacy in preclinical in vivo models and summarizes findings from early-phase clinical trials. Despite encouraging preclinical results, challenges such as drug resistance, limited bioavailability, and barriers to clinical translation remain.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anticancer properties of Artemisia species: mechanisms and experimental evidence

  • 期刊论文

  • 发表日期：

    2026年3月20日

查看全文
  • Abdulmunem M. Abulayha,
  • Eman Eshawesh,
  • Esam Alshareef,
  • Fawzi Ebrahim,
  • Adam Elzagheid

摘要

The genus Artemisia (family Asteraceae) is widely recognized for its medicinal properties, among which artemisinin is the most notable, historically serving as a key antimalarial agent. Accumulating evidence now highlights the significant anticancer potential of Artemisia species, with bioactive compounds such as artemisinin and its derivatives exhibiting promising activity across multiple cancer types. This review provides a comprehensive overview of the molecular mechanisms underlying the anticancer effects of Artemisia-derived compounds, including apoptosis induction, cell cycle arrest, and oxidative stress modulation. In addition, it examines their therapeutic efficacy in preclinical in vivo models and summarizes findings from early-phase clinical trials. Despite encouraging preclinical results, challenges such as drug resistance, limited bioavailability, and barriers to clinical translation remain.